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Abstract
Background: Collision tumors are uncommon but well described clinical entities composed of distinct tumor
histologies occurring within the same anatomic site. Optimal management of patients with collision tumors
remains highly variable and depends on clinical characteristics such as the involved tumor types, predominant
histology, as well as the extent of disease. Comprehensive genomic profiling is a means of identifying genomic
alterations to suggest benefit from targeted therapy.
Case presentation: A 78-year-old woman presented to medical oncology with liver metastases occurring within
the background of a 1-year history of uveal melanoma. Biopsy of the liver metastases revealed presence of
adenocarcinoma along with nests of malignant melanoma consistent with a collision tumor. The disease was
refractory to several lines of conventional cytotoxic chemotherapy, and the patient later developed pulmonary
metastases while on chemotherapy. The patient’s tumor tissue was assayed by comprehensive genomic profiling
which revealed presence of a TSC1 partial loss. The patient was subsequently initiated on temsirolimus 15 mg
intravenously weekly for 4 months. Restaging imaging demonstrated a partial response to therapy by RECIST 1.1
criteria and clinical benefit for 6 months until the patient passed away secondary to unrelated causes.
Conclusions: We report the first case of a collision tumor composed of adenocarcinoma and melanoma with a
TSC1 mutation that objectively and durably responded to mTOR inhibition.
Keywords: Collision tumor, Uveal melanoma, TSC1 mutation, mTOR inhibition, Temsirolimus, Carcinoma
Undetermined Primary, Melanoma, Next Generation Sequencing, Case Report
Background
Cancer therapy continues to move towards the targeting
of molecular signaling pathways; mTOR inhibitors have
been well studied since the early 1990s with increasing
recognition immunosuppressive and anticancer proper-
ties. In particular, the TSC1-TSC2 complex has emerged
as an integral signal involved in the inhibition of
mTORC1. Inactivating alterations of tumor suppressor
genes TSC1 and TSC2 have been implicated in tuberous
sclerosis and a wide variety of malignancies in which
mTORC1 was found to be highly activated [1]. Promis-
ing clinical trials have shown that tumors harboring
TSC1 mutations respond to mTOR inhibitors and the
clinical significance of such a mutation is highlighted in
the present case [1].
We present a patient with a prior diagnosis of uveal
melanoma with new metastatic hepatic disease for
whom biopsy unexpectedly demonstrated a collision
tumor of melanoma and adenocarcinoma of unknown
primary. Although collision tumors have been described
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in literature, primarily between two cutaneous malignan-
cies, a combination of melanoma and adenocarcinoma is
extremely rare with only a few reported cases [2–5]. The
patient did not respond to several conventional chemo-
therapy agents but did respond to targeted mTOR inhib-
ition after genomic sequencing revealed the presence of
a TSC1 mutation. This case highlights two unique facets
in both the phenomenon of collision tumors and the sig-
nificance of targeted signaling pathway agents where
traditional chemotherapy has failed.
Case presentation
A 78-year-old woman presented to our institution for
further management of newly diagnosed metastatic liver
disease.
The patient initially presented with symptoms of de-
creased visual acuity of the right eye 1 year prior. Com-
prehensive physical examination was unrevealing. The
patient was referred to ophthalmology and was diag-
nosed with choroidal melanoma. The tumor initially
measured 19.5 x 13.6 mm and involved 50% of the optic
nerve head as well as the macula. The patient was
treated with radiotherapy along with transpupillary
thermotherapy.
As part of routine surveillance for the diagnosis of
uveal melanoma, the patient was followed with serial CT
scans of the abdomen and pelvis every 3 months. Nine
months after the initial diagnosis repeat CT scan re-
vealed multiple liver masses suggestive of metastatic dis-
ease involving the lateral segment of the left hepatic
lobe. A dominant mass was identified measuring 6.9 x
5.8 cm and the patient was referred for core needle bi-
opsy. Pathology revealed abundant involvement by
adenocarcinoma, which stained positive for pankeratin
(AE1/AE3), CK7, CK20 (Fig. 1). Additionally, several
nests of atypical cells with cytoplasmic pigmentation
consistent with malignant melanoma were identified.
Immunohistochemical stains showed the malignant pig-
mented neoplasm to be negative for AE1/AE3 and posi-
tive for S100, SOX10, HMB45 (Fig. 1).
Fig. 1 Core-needle liver biopsy. a low-powered field showing melanoma (left) and adenocarcinoma (right). b 40x view of melanoma. c S-100 stain.
d 40x of carcinoma. e Pankeratin stain. f SOX10 stain. g CK7 stain. h CK20 stain. i HMB-45 stain
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Given the unexpected findings of metastatic adenocar-
cinoma co-existing with metastatic melanoma, a diagnos-
tic workup was done to identify the site of origin for the
adenocarcinoma component. Whole-body PET/CT, and
upper and lower endoscopy failed to identify the primary
anatomic site. The patient was therefore diagnosed with
metastatic collision tumor composed of adenocarcinoma
of unknown primary along with malignant melanoma and
empiric chemotherapy was initiated. Unfortunately, the
disease proved refractory to several lines of conventional
cytotoxic chemotherapy. She received two cycles of oral
capecitabine (Xeloda, Genentech, South San Francisco,
CA; 1000 mg/m2 orally day 1–14 every 21 days). This was
discontinued secondary to grade 2–3 gastrointestinal tox-
icity (nausea, vomiting). The patient subsequently received
8 cycles of gemcitabine (Gemzar, Eli Lilly, Indianapolis, IN;
900 mg/m2 IV day 1, 8 every 21 days;) combined with
protein-bound nab-paclitaxel (Abraxane, Celgene, Summit,
NJ; 100 mg/m2 IV day 1, 8, 15 every 28 days). Restaging
imaging revealed progressive disease in the liver as well as
the interval development of metastatic lung nodules.
The patient’s tissue was submitted as a formalin-fixed,
paraffin-embedded block to a CLIA-certified, CAP-
accredited laboratory (Foundation Medicine, Cambridge,
MA) for CGP. DNA was extracted from the tumor spe-
cimen. Hybrid-capture-based CGP using next-generation
sequencing was performed of the entire coding se-
quence. This included 236 genes and 47 introns of 19
genes involved in fusions at a depth of X500. Alterations
were identified as point mutations, deletions, amplifica-
tions, duplications, insertions, rearrangements, and
splice variants. These were characterized as known or
likely pathogenic changes as reported by the Foundatio-
nOne assay.
DNA extracted from the biopsy of the collision tumor
submitted for NGS contained both melanoma and
adenocarcinoma. Several genomic alterations were iden-
tified as follows TSC1 loss (homozygous deletion) of
exons 20-23, CDKN2A/B loss, BAP1 (E20fs*52), PBRM1
(R1095fs*39). CGP is a validated approach in detecting
base substitutions, short insertions, deletions, copy num-
ber alterations and selected fusion products. The tech-
nique has been directly compared to established assays
including PCR. Test sensitivity approximately 95–99%
across various alteration types with high specificity (posi-
tive predictive value >99%). Because CGP is a validated
technique to identify genetic abnormalities, no add-
itional testing on the tumor sample was clinically indi-
cated [6].
Tuberous sclerosis gene 1 (TSC1) is a tumor suppressor
gene found on the long arm of chromosome 9. TSC1 en-
codes the protein gene product hamartin composed of
one transmembrane domain and two coiled-coil domains.
The first coiled-coil domain modulates interaction
between hamartin and tuberin. A second coiled-coil do-
main is encoded by exons 17 to 23 which stabilizes the
tuberin-hamartin complex [7]. The hamartin-tuberin
complex enables the GTPase-activating function of
tuberin and is a major regulator of small G-protein Rheb
which interacts with mTORC1 [8, 9]. Loss of hamartin,
therefore results in increased downstream mTOR activity
potentially predicting increased sensitivity to mTOR
inhibitors.
Based on the results of CGP the patient began treat-
ment with temsirolimus (Torisel, Pfizer, New York, NY)
15 mg intravenously weekly. The patient was followed
with clinical examinations monthly and restaging im-
aging every 2 months while on therapy. After 4 months
of treatment, a restaging CT scan of the chest, abdomen,
and pelvis demonstrated a significant partial response to
therapy by RECIST 1.1 criteria (Fig. 2). Restaging im-
aging 2 months later demonstrated stable disease. The
patient experienced no dose-limiting toxicities while on
therapy. Unfortunately, the patient later developed se-
vere sepsis related to Clostridium Difficile colitis and
died from infectious complications 6 months after
Fig. 2 Pre-treatment and post-treatment imaging. a Pre-treatment
CT scan of liver. b Post-treatment CT scan of liver
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starting temsirolimus. Informed consent was obtained
for the publication of this manuscript and available to
the journal editors for review. This manuscript adhered
to CARE guidelines for case reports.
Discussion
A collision tumor is an uncommon occurrence in which
two distinct tumor histologies are present in a single
anatomic site. Under the World Health Organization
(WHO) histological classification guidelines, a collision
tumor should comprise at least two different malignant
components with no mixed or transitional area between
[10, 11]. Several theories have been proposed to explain
the pathophysiology of this phenomenon. One mechan-
ism involves the alteration of the tumor microenviron-
ment facilitating colonization or metastases of tumor to
that site. An alternative model would be a coincidental
meeting of two primary tumors. In contra-distinction, a
composite tumor references a tumor that evolves into
two distinct histologies from presumably a pluripotent
precursor cancer stem cell.
Although cases of synchronous adenocarcinoma and
melanoma have been reported, the presentation remains
exceedingly rare [2–5]. The clinical behavior and natural
history of collision tumors may reflect the biology of the
more aggressive tumor involved [11]. In general, both
metastatic adenocarcinoma of undetermined primary
and metastatic ocular melanoma are associated with
poor prognoses. It is unknown whether or not the pres-
ence of a collision tumor portends a worse prognosis
than either condition alone.
Mutations in TSC1 and TSC2 have been reported in a
variety of neoplasms and benign tumors including pul-
monary lymphangioleiomyomatosis (LAM), perivascular
epitheloid cell tumors (PEComa), urothelial carcinomas,
renal cell carcinoma and hepatocellular carcinomas [12].
Mutations in the tuberous sclerosis complex (TSC) has
been reported in up to 14.5% of bladder cancer and
28.6% of hepatocellular carcinoma [13, 14]. Alterations
resulting in PTEN loss and PIK3CA amplification, which
are also targets for mTOR/P13K inhibitors, have been
implicated in 7% and 9% respectively, in carcinomas of
unknown primary [15]. Of greater clinical relevance, the
presence of mutations involving TSC1 or TSC2 may pre-
dict a response to downstream inhibition of the mTOR
pathway [1, 7].
This patient’s disease had been highly refractory to con-
ventional chemotherapeutic agents, but did demonstrate
sensitivity to temsirolimus. In addition, the patient’s CGP
demonstrated mutation of BRCA1-associated protein 1
(BAP1) gene, which is frequently inactivated in metastatic
uveal melanomas [16]. BAP1 encodes a nuclear ubiquitin
carboxyterminal hydrolase, which is a class of deubiquiti-
nating enzymes, and contains binding domains for BRCA1
and BARD1 to form a tumor suppressor complex among
other functions [16]. In uveal melanomas, somatic inacti-
vating mutations of BAP1 have been highly associated
with onset of metastatic behavior thus suggesting a poten-
tial novel target for therapy [16].
Additionally, noted on NGS were alterations in
CDKN2A/2B as well as PBRM1. CDKN2A/2B encode
tumor suppressor gene products cyclin-dependent kinase
4 inhibitor A/B. This gene encodes a cycle-dependent kin-
ase inhibitor that prevents activation of the CDK kinases
thereby inhibiting cell cycle G1 progression [17, 18]. Inter-
estingly, germ line mutations in CDKN2A have been asso-
ciated with familial melanoma syndromes and may have
reflected genetic alterations from this patient’s uveal mel-
anoma. PBRM1 encodes Polybromo-1 (BAF180) which is
a subunit of ATP-dependent chromatin-remodeling com-
plex. It has an additional role as a cofactor in transactiva-
tion of nuclear hormone receptors [19]. This abnormality
is most closely associated with clear cell renal cell carcin-
oma occurring in up to 30% of cases. In addition, it has
been reported in up to 2–4% of colorectal adenocarcin-
oma [20, 21]. Unfortunately, no FDA approved therapies
targeting CDKN2A/B or PBRM1 are currently available. If
additional targeted agents had been available, combination
therapy may have been an important treatment consider-
ation in management of this patient’s disease.
In our patient, disease progression on multiple lines of
cytotoxic chemotherapy suggests that targeted inhibition of
mTOR pathway was critical in inducing tumor response.
Because tissue composed of both adenocarcinoma and mel-
anoma was submitted for NGS, it is unknown whether the
genetic alterations observed were unique to either tumor
histology. Given the radiographic response to therapy with
mTOR inhibitor, no repeat biopsy was clinically indicated.
Nonetheless, the potential of detecting significant thera-
peutic targets implies that patients with refractory collision
tumors would benefit from genomic profiling.
Conclusion
To our knowledge, this is the first case of a collision
tumor composed of adenocarcinoma and melanoma with
a mutation of the TSC1 gene locus. The objective clinical
response achieved with targeted inhibition of the mTOR
pathway further highlights the clinical significance of the
genetic alteration identified by NGS. As a result, NGS
may have a potential utility in identifying actionable tar-
gets in collision tumors failing to response to traditional
cytotoxic chemotherapy. Further investigation into the
identification of driver genetic mutations in collision tu-
mors and potential therapeutic targets is warranted.
Abbreviations
BAP1: BRCA1 associated protein 1; BARD1: BRCA1 Associated RING Domain 1;
BRCA1: Breast cancer type 1 susceptibility protein; CDKN2A/B: Cyclin-
dependent kinase inhibitor 2A/B; CGP: Comprehensive genomic profiling;
Bhangoo et al. BMC Cancer  (2017) 17:197 Page 4 of 5
CK: Cytokeratin; CLIA: Clinical Laboratory Improvement Act; CT: Computerized
tomography; GNAQ: G protein subunit alpha q; GNAS: G protein subunit
alpha S; GTPase: Guanosine-5’-triphosphate hydrolase; HMB45: Human
Melanoma Black common marker to confirm melanoma; mTOR: Mammalian
target of rapamycin; P13K: Phosphatidylinositide 3-kinases; PET/CT: Positron
emission tomography computerized tomography;
PIK3CA: Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit
alpha; PRM1: Protein polybromo-1; PTEN: Phosphatase and tensin homolog;
RECIST: Response Evaluation Criteria in Solid Tumors; S100 protein: Common
marker for neural tissues and melanoma; SOX: Sry-related HMG box;
TSC: Tuberous sclerosis
Acknowledgements
We thank Dr. Eric Chao, radiology and Dr. John Hughes, pathology for their
contribution in selecting images for the case.
Funding
None.
Availability of data and material
Data sharing not applicable to this article as no datasets were generated or
analysed during the current study.
Authors’ contributions
The manuscript was written by MB, JZ, and CC. SA, RM and AS reviewed the
manuscript and contributed to planning of the review. All the authors have
read and approved the manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Written informed consent was obtained from the patient for publication of
this Case Report. A copy of the written consent is available for review by the
Editor of this journal.
Ethics approval and consent to participate
Not applicable to this submission
Author details
1Division of Hematology Oncology, Scripps Clinic, 10666 N. Torrey Pines Ave,
La Jolla, CA 92037, USA. 2Department of Internal Medicine, Scripps Mercy
Hospital, San Diego, CA, USA. 3Foundation Medicine, Cambridge, MA, USA.
Received: 21 July 2016 Accepted: 2 March 2017
References
1. Wander S, Hennessy B, Slinglerland J. Next-generation mTOR inhibitors in
clinical oncology: how pathway complexity informs therapeutic strategy. J
Clin Invest. 2011;121(4):1231–41.
2. Lim A, Grant B, Avramovic J, Ho YH, Wallace C. Synchronous primary
anorectal melanoma and sigmoid adenocarcinoma: a case report. Int Surg.
2015;100(5):814–7.
3. Dias AR, Pinto RA, Mory E, Silva IC, Siqueira SA, Nahas SC, Cecconello I,
Wexner SD. Synchronous collision malignant melanoma and
adenocarcinoma of the rectum. Tech Coloproctol. 2010;14(2):181–4.
4. Ueyama T, Tsuru T, Tsuneyoshi M, Sueishi K, Sibuya T, Fukuda T. Primary
collision neoplasm of malignant melanoma and adenocarcinoma in the
lung. A case report. Pathol Res Pract. 1993;189(2):178–83.
5. Inoshita T, Laurain AR, Youngberg GA, Musil G. Metastasis of bronchogenic
carcinoma to the skin involved by melanoma. Arch Pathol Lab Med. 1984;
108(7):595–8.
6. Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation
of a clinical cancer genomic profiling test based on massively parallel DNA
sequencing. Nat Biotechnol. 2013;31(11):1023–31.
7. Sun W, Zhu YJ, Wang Z, Zhong Q, Gao F, Lou J, Gong W, Xu W. Crystal
structure of the yeast TSC1 core domain and implications for tuberous
sclerosis pathological mutations. Nat Commun. 2013;4:2135.
8. Han JM, Sahin M. TSC1/TSC2 signaling in the CNS. FEBS Lett. 2011;585:973–80.
9. Inoki K, Li Y, Xu T, Guan KL. Rheb GTPase is a direct target of TSC2 GAP
activity and regulates mTOR signaling. Genes Dev. 2003;17:1829–34.
10. Hirono S, Tani M, Terasawa H, Kawai M, Ina S, Uchiyama K, et al. A collision
tumor composed of cancers of the bile duct and ampulla of Vater -
immunohistochemical analysis of a rare entity of double cancer.
Hepatogastroenterology. 2008;55:861–4.
11. Stukavec J, Jirasek T, Mandys V, Denemark L, Havluj L, Sosna B, Kosmahl M,
Zadorova Z. Poorly differentiated endocrine carcinoma and intraductal
papillary-mucinous neoplasm of the pancreas: description of an unusual
case. Pathol Res Pract. 2007;203:879–84.
12. Northrup H, Koenig MK, Pearson DA, Au KS. Tuberous sclerosis complex. In
GeneReviews. Edited by Pagon RA, Adam MP, Ardinger HH, Wallace SE,
Amemiya A, Bean LJH, Bird TD, Fong CT, Mefford HC, Smith RJH, Stephens K.
Seattle (WA): University of Washington, Seattle; 1993-2016. [http://www.ncbi.
nlm.nih.gov/books/NBK1220/?report=printable]. Accessed on 22 Apr 2016.
13. Knowles MA, Habuchi T, Kennedy W, Cuthbert-Heavens D. Mutation
spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell
carcinoma of the bladder. Cancer Res. 2003;63:7652–6.
14. Huynh H, Hao HX, Chan SL, Chen D, Ong R, Soo KC, Pochanard P, Yang D,
Ruddy D, Liu M, Derti A, Balak MN, Palmer MR, Wang Y, Lee BH, Sellami D,
Zhu AX, Schlegel R, Huang A. Loss of tuberous sclerosis complex 2 (TSC2) is
frequent in hepatocellular carcinoma and predicts response to mTORC1
inhibitor everolimus. Mol Cancer Ther. 2015;14(5):1224–35.
15. Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, Palmer G, Yelensky R, Lipson
DM, Chmielecki J, Erlich RL, Rankin AN, Ali SM, Elvin JA, Morosini D, Miller VA,
Stephens PJ. Comprehensive genomic profiling of carcinoma of unknown
primary site: new routes to targeted therapies. JAMA Oncol. 2015;1(1):40–9.
16. Harbour JW, Onken MO, Roberson EDO, Duan S, Cao L, Worley LA, Council
ML, Matatall KA, Helms C, Bowcock AM. Freqeunt mutation of BAP1 in
metastasizing uveal melanomas. Science. 2010;330(6009):1410–3.
17. Gazzeri S, Gouyer V, Vourch C, Brambilla C, Brambilla E. Mechanisms of p16INK4A
inactivation in non-small-cell lung cancers. Oncogene. 1998;16(4):497–504.
18. Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene.
1999;18(38):5311–7.
19. Lemon B, Inouye C, King DS, Tijan R. Selectivity of chromatin-remodeling
cofactors for ligand-activated transcription. Nature. 2001;414(6866):924–8.
20. Cancer Genome Atlas Research Network. Comprehensive molecular
characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–9.
21. Cancer Genome Atlas Research Network. Comprehensive molecular
characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bhangoo et al. BMC Cancer  (2017) 17:197 Page 5 of 5
